Remibrutinib

Novartis has been steadily dialing back its U.S. workforce in recent years. Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to eliminate 114 positions as the drugmaker rejigs its sales team for rare-disease medicines.The Swiss pharma telegraphed the layoffs in a recent Worker Adjustment and Retraining Notification (WARN) filing (PDF) to the state, with the cuts slated to take effect from late June to November. “[O]ur US Customer Engagement organization has been evaluating opportunities to evolve our field sales team structures to better support the unique needs of patients and customers in the rare and ultra-rare disease spaces—where Novartis has a strong footprint and focus with in-market products and upcoming pivotal launches,” a Novartis spokesperson told Fierce Pharma. “To that end, we are making some organizational changes that result in some roles being eliminated, modified, and created.”  The adjustment marks the latest in a series of layoffs at Novartis, which can be traced all the way back to a major reorganization launched in 2022. Novartis offers several drugs in the rare disease space. These include chronic myeloid leukemia therapy Tasigna and Promacta for treating low blood platelet counts in certain patients, including those with the rare blood disorders chronic immune thrombocytopenia (ITP) and aplastic anemia. The two meds, together with the megablockbuster heart failure treatment Entresto, form the largest single-year patent cliff in Novartis’ history, presenting a notable challenge for the company in 2026.Novartis is also managing a few new rare disease launches in the autoimmune field, including Rhapsido for chronic spontaneous urticaria (CSU). It’s additionally rolling out two rare kidney disease therapies, Vanrafia and Fabhalta, in IgA nephropathy. Further, the dual-mechanism, B-cell-depleting antibody ianalumab is nearing the market after a pair of phase 3 wins in Sjögren’s, while a first-line ITP pivotal readout is expected this year. “Novartis continually assesses opportunities to adapt in alignment with our evolving pipeline, patient, and customer needs. As such, we direct our efforts and talent toward areas where we can create the greatest potential impact for patients and customers,” the company spokesperson said.  Novartis has made multiple cuts tied to its New Jersey HQ in the past few years. In September, it laid out a plan to lay off 58 employees in its U.S. medical affairs organization, following another overhaul of its cardiovascular commercial structure that affected 427 employees.The Swiss pharma has been steadily dialing back its U.S. workforce in recent years. Coinciding with the separation of the biosimilars and generics unit Sandoz, Novartis’ U.S. headcount, measured by full-time equivalents, dropped by nearly 12% year over year to 12,846 in 2023. As of the end of last year, the company had 12,556 full-time employees stateside. Globally, Novartis is only one of two large pharma companies that have consistently slimmed down every year between 2021 and 2025, according to a recent Fierce Pharma analysis.  While its U.S. commercial team and general and administrative functions have become smaller, Novartis beefed up its manufacturing headcount by 25% last year to 1,479 people. Following an industry-wide trend to avoid potential pharmaceutical tariffs by the Trump administration, Novartis last year unveiled a $23 billion investment to grow its U.S. footprint in production and R&D.  

New Rhapsido ® REMIX-1 & -2 pooled analysis on symptom control as early as week 1 in chronic spontaneous urticaria (CSU) to be presented Long-term Cosentyx ® data build on extensive body of evidence supporting continuous use in hidradenitis suppurativa (HS) and psoriasis Additional Cosentyx data in HS include indirect comparison of efficacy and safety vs bimekizumab Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting. Presentations include new Rhapsido ® (remibrutinib) data highlighting changes in daily itch and hives severity scores at week 1 in patients with chronic spontaneous urticaria (CSU), an indirect comparison on Cosentyx ® (secukinumab) safety and flare prevention for patients with hidradenitis suppurativa (HS) vs. bimekizumab, as well as 4- and 5-year efficacy data from pivotal trials in HS and psoriasis, respectively. “Novartis data at this year’s AAD build on the robust body of evidence for the use of Rhapsido and Cosentyx in their approved dermatological indications,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “These presentations also demonstrate the strength of our immunology portfolio and our ongoing efforts to help patients manage chronic diseases that significantly impact their lives and overall well-being.” Key abstracts accepted by AAD include: Molecule/disease state Abstract title Abstract number/ presentation details Rhapsido ® (remibrutinib) CSU Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies Abstract #71668 e-Poster & Oral Presentation March 27, 3:15 pm MT Design of the REASSERT Study: A prospective, multi-country, noninterventional effectiveness and safety study evaluating remibrutinib in patients worldwide with chronic spontaneous urticaria (CSU) Abstract #72973 e-Poster March 27 Burden of disease Urticaria Voices: Treatment patterns and disease control in patients with self-reported chronic inducible urticaria Abstract #75145 e-Poster March 27 Cosentyx ® (secukinumab) HS Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa: A matched adjusted indirect comparison analysis of Phase 3 trials Abstract #76852 e-Poster & Oral Presentation Mar 27, 1:45 pm MT Designing a secukinumab dosing regimen in adolescents with moderate to severe hidradenitis suppurativa using model-informed drug development Abstract #74494 e-Poster & Oral Presentation March 28, 2:00 pm MT Four-year efficacy of continuous secukinumab in SUNSHINE/SUNRISE core and extension trials on hidradenitis suppurativa (HS) lesions Abstract #75099 e-Poster March 27 Psoriatic arthritis Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients With Moderate to Severe Psoriasis Abstract #73859 e-Poster & Oral Presentation March 28, 11:45 am MT Impact of Disease Duration on the Treatment Effect of Secukinumab in the Prevention of Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis: A 5-year Pooled Analysis of the ERASURE, FIXTURE and SCULPTURE Studies Abstract #74500 e-Poster & Oral Presentation March 28, 2:05 pm MT About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. Product Information For full prescribing information, including approved indications and important safety information about marketed products, please visit . Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com